CN117442510A - Anti-wrinkle composition based on Sirt signal channel, and preparation method and application thereof - Google Patents
Anti-wrinkle composition based on Sirt signal channel, and preparation method and application thereof Download PDFInfo
- Publication number
- CN117442510A CN117442510A CN202311439515.7A CN202311439515A CN117442510A CN 117442510 A CN117442510 A CN 117442510A CN 202311439515 A CN202311439515 A CN 202311439515A CN 117442510 A CN117442510 A CN 117442510A
- Authority
- CN
- China
- Prior art keywords
- enzyme
- sirt
- composition based
- ginsenoside
- wrinkle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000001153 anti-wrinkle effect Effects 0.000 title claims abstract description 40
- 239000000203 mixture Substances 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title abstract description 5
- 102000004190 Enzymes Human genes 0.000 claims abstract description 29
- 108090000790 Enzymes Proteins 0.000 claims abstract description 29
- 239000000284 extract Substances 0.000 claims abstract description 18
- 238000000855 fermentation Methods 0.000 claims abstract description 18
- 230000004151 fermentation Effects 0.000 claims abstract description 18
- 239000000411 inducer Substances 0.000 claims abstract description 9
- 238000006911 enzymatic reaction Methods 0.000 claims abstract description 7
- 241000190633 Cordyceps Species 0.000 claims abstract description 6
- 235000014897 Streptococcus lactis Nutrition 0.000 claims abstract description 6
- 238000012258 culturing Methods 0.000 claims abstract description 6
- 240000000599 Lentinula edodes Species 0.000 claims abstract description 5
- 235000001715 Lentinula edodes Nutrition 0.000 claims abstract description 5
- YQKCHRBAJSATCG-UHFFFAOYSA-N UNPD30744 Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC(C)(CCC=C(C)C)C2C3C(C4(CCC5C(C)(C)C(OC6C(C(O)C(O)C(CO)O6)OC6C(C(O)C(O)C(CO)O6)O)CCC5(C)C4CC3O)C)(C)CC2)O1 YQKCHRBAJSATCG-UHFFFAOYSA-N 0.000 claims abstract description 5
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 claims abstract description 5
- NODILNFGTFIURN-USYOXQFSSA-N ginsenoside Rb3 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O NODILNFGTFIURN-USYOXQFSSA-N 0.000 claims abstract description 5
- PFSIGTQOILYIIU-UHFFFAOYSA-N ginsenoside Rb3 Natural products CC(=CCCC(C)(O)C1CCC2(C)C3CCC4C(C)(C)C(CCC4(C)C3CC(OC5OC(COC6OCC(O)C(O)C6O)C(O)C(O)C5O)C12C)OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C PFSIGTQOILYIIU-UHFFFAOYSA-N 0.000 claims abstract description 5
- UVBLDLGZDSGCSN-UHFFFAOYSA-N ginsenoside-Rb3 Natural products C1=CC2C3(C)CCC(O)C(C)(C)C3CCC2(C)C2(C)CCC34CCC(C)C(C)C4C21OC3=O UVBLDLGZDSGCSN-UHFFFAOYSA-N 0.000 claims abstract description 5
- 238000000746 purification Methods 0.000 claims abstract description 4
- 241000194035 Lactococcus lactis Species 0.000 claims abstract 2
- 238000000605 extraction Methods 0.000 claims abstract 2
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- 239000000243 solution Substances 0.000 claims description 33
- 230000019491 signal transduction Effects 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 16
- 229930182494 ginsenoside Natural products 0.000 claims description 13
- 229940089161 ginsenoside Drugs 0.000 claims description 13
- 239000008055 phosphate buffer solution Substances 0.000 claims description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- 239000000758 substrate Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 4
- 239000008363 phosphate buffer Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 3
- 244000068988 Glycine max Species 0.000 claims description 3
- 235000010469 Glycine max Nutrition 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 235000010323 ascorbic acid Nutrition 0.000 claims description 3
- 229960005070 ascorbic acid Drugs 0.000 claims description 3
- 239000011668 ascorbic acid Substances 0.000 claims description 3
- YXVFQADLFFNVDS-UHFFFAOYSA-N diammonium citrate Chemical compound [NH4+].[NH4+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O YXVFQADLFFNVDS-UHFFFAOYSA-N 0.000 claims description 3
- FVIZARNDLVOMSU-IRFFNABBSA-N ginsenoside C-K Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FVIZARNDLVOMSU-IRFFNABBSA-N 0.000 claims description 3
- 235000013922 glutamic acid Nutrition 0.000 claims description 3
- 239000004220 glutamic acid Substances 0.000 claims description 3
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 claims description 3
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims description 3
- 235000008696 isoflavones Nutrition 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 229920000855 Fucoidan Polymers 0.000 claims description 2
- BXVSAYBZSGIURM-UHFFFAOYSA-N 2-phenoxy-4h-1,3,2$l^{5}-benzodioxaphosphinine 2-oxide Chemical compound O1CC2=CC=CC=C2OP1(=O)OC1=CC=CC=C1 BXVSAYBZSGIURM-UHFFFAOYSA-N 0.000 claims 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims 1
- 241000212941 Glehnia Species 0.000 claims 1
- 241000382353 Pupa Species 0.000 claims 1
- 229930003779 Vitamin B12 Natural products 0.000 claims 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims 1
- 235000013336 milk Nutrition 0.000 claims 1
- 239000008267 milk Substances 0.000 claims 1
- 210000004080 milk Anatomy 0.000 claims 1
- 235000019163 vitamin B12 Nutrition 0.000 claims 1
- 239000011715 vitamin B12 Substances 0.000 claims 1
- 230000003712 anti-aging effect Effects 0.000 abstract description 9
- 239000002537 cosmetic Substances 0.000 abstract description 5
- 230000037303 wrinkles Effects 0.000 description 45
- 239000000047 product Substances 0.000 description 32
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 23
- 241000700159 Rattus Species 0.000 description 17
- 102000000344 Sirtuin 1 Human genes 0.000 description 14
- 108010041191 Sirtuin 1 Proteins 0.000 description 14
- 229930182490 saponin Natural products 0.000 description 14
- 150000007949 saponins Chemical class 0.000 description 14
- 235000017709 saponins Nutrition 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 12
- 210000004185 liver Anatomy 0.000 description 11
- 235000015097 nutrients Nutrition 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108010009306 Forkhead Box Protein O1 Proteins 0.000 description 9
- 102000009561 Forkhead Box Protein O1 Human genes 0.000 description 9
- 230000008859 change Effects 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 238000001514 detection method Methods 0.000 description 8
- 150000004676 glycans Chemical class 0.000 description 8
- 229920001282 polysaccharide Polymers 0.000 description 8
- 239000005017 polysaccharide Substances 0.000 description 8
- 241000208340 Araliaceae Species 0.000 description 7
- 102000023984 PPAR alpha Human genes 0.000 description 7
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 7
- 235000003140 Panax quinquefolius Nutrition 0.000 description 7
- 235000008434 ginseng Nutrition 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 239000012528 membrane Substances 0.000 description 5
- 244000057717 Streptococcus lactis Species 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 238000009630 liquid culture Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241001052560 Thallis Species 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 230000009759 skin aging Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 238000012353 t test Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 241000255789 Bombyx mori Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 102000003921 Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha Human genes 0.000 description 2
- 108090000310 Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha Proteins 0.000 description 2
- 229930003270 Vitamin B Natural products 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 235000020247 cow milk Nutrition 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 230000009758 senescence Effects 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 235000015193 tomato juice Nutrition 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P33/00—Preparation of steroids
- C12P33/20—Preparation of steroids containing heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/805—Corresponding aspects not provided for by any of codes A61K2800/81 - A61K2800/95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/46—Streptococcus ; Enterococcus; Lactococcus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Cosmetics (AREA)
Abstract
The invention provides a preparation method of an anti-wrinkle composition based on a Sirt signal channel, which comprises the steps of strain culture, enzyme production by fermentation, enzyme extraction, enzyme reaction and purification; the strain is lactococcus lactis subspecies lactis. The fermentation produces enzyme: the fermentation temperature is 36-38 ℃, and after culturing for 24-28 hours, the inducer is added for continuous culturing for 24-36 hours, thus obtaining the enzyme-containing culture solution. The inducer comprises ginsenoside Rb3, lentinus Edodes extract, cordyceps extract, and radix Glehniae extract. The anti-wrinkle composition prepared by the invention has excellent anti-aging effect, can be used for preparing cosmetics, and has obvious anti-wrinkle and anti-wrinkle effects.
Description
Technical Field
The invention relates to the technical field of skin care, in particular to an anti-wrinkle composition based on Sirt signal channels, and a preparation method and application thereof.
Background
With increasing importance of skin care, functional cosmetics face unprecedented opportunities, so that finding cosmetic raw materials with anti-wrinkle, anti-aging and other functions becomes the biggest pain point in the cosmetic industry, and is also the biggest requirement. As a pain in Chinese herbal medicine, ginseng plays an excellent role in wrinkle resistance, and thus, its active ingredient is also a potential candidate with great development value. However, research shows that natural protopanaxoside contained in ginseng belongs to polysaccharide-based ginsenoside, is difficult to directly penetrate cell membranes and be absorbed, and after the ginseng product is orally taken, the polysaccharide-based ginsenoside is degraded into low-sugar-based ginsenoside metabolites in digestive juice and intestinal bacteria in the digestive system, and then can be absorbed and utilized. When the ginseng product is externally used, intestinal bacteria capable of metabolizing ginsenoside are not arranged on the skin, and the ginsenoside exists in a polysaccharide-based prototype, so that the availability is extremely low. Therefore, the modification of the polysaccharide-based saponin into the low-sugar-based saponin has extremely important significance for the development of external products.
Currently, there are mainly four aspects of the mechanism of anti-skin aging: inflammatory signaling pathways, nrf2 signaling pathways, MAPK signaling pathways, and NF- κb signaling pathways, common factors that cause skin aging, such as UVB, ROS, exposure groups, etc., are all associated with these four signaling pathways. However, sirt signaling pathways, which have important effects on cellular aging and are known as "longevity genes", have been less studied for their use in combating skin aging. The Sirt signal channel has important regulation effect on the material metabolism and the energy metabolism of cells, has direct or indirect connection with the aging of the cells through various ways, and is a potential important way for developing anti-skin aging and anti-wrinkle technologies. A schematic of the mechanism by which Sirt signaling channels affect cell senescence is shown in fig. 8. Therefore, the development of products acting on Sirt signal channels is of great importance for the development of techniques against skin aging.
In the prior art, no product for realizing anti-aging and wrinkle removal by regulating the expression of a Sirt signal channel exists.
Disclosure of Invention
Aiming at the technical problems, the invention provides an anti-wrinkle composition based on a Sirt signal channel, a preparation method and application thereof, and aims to achieve the following purposes: promoting Sirt1 expression and realizing remarkable anti-wrinkle and anti-wrinkle effects.
In order to achieve the aim of the invention, the invention adopts the following technical scheme:
a method of preparing an anti-wrinkle composition based on Sirt signaling pathways comprising the steps of:
step 1, strain culture
Inoculating lactococcus lactis subspecies into a liquid culture medium under the conditions of normal temperature and normal pressure; the formula of the liquid culture medium is as follows:
yeast extract 7.5 g, glucose 10.0 g, tomato juice (pressed juice) 100.0 mL, protein wine 7.5 g, KH 2 PO 4 2.0g, tween 800.5 mL, distilled water 900.0 mL, pH 7.0.
The lactococcus lactis subspecies: the strain is commercially available and the strain preservation number is CICC 20402.
After inoculation, the culture is carried out for 35 to 38 hours under the condition of 37 ℃ and oxygen.
Step 2, fermenting to produce enzyme
After 36 hours of cultivation, the culture broth was transferred to a fermentation medium with an inoculum size of 1-2%.
The fermentation medium is as follows: 40-44g of ginseng total saponins, 4.5-6g of silkworm chrysalis meal, 3.5-5g of cow milk meal, 1.8-2.2g of soybean isoflavone, 1.8-2.3g of mannitol, 0.9-1.3g of diammonium citrate, 0.9-1.1g of ascorbic acid, 0.8-1.2g of vitamin B and K 2 HPO 4 0.25-0.35g、ZnSO 4 ·7H 2 O 0.15-0.25g、MnSO 4 ·H 2 O 0.05-0.06g、(NH 4 )SO 4 ·H 2 O 0.05-0.06g、Ca(NO 3 ) 2 0.8-1.2g, fucoidin 5-7g, glutamic acid 0.8-1.2g, distilled water 1.0L, pH6.8-7.0. Culturing at 36-38deg.C for 24-28 hr, adding inducer, shaking the culture medium, and culturing for 24-36 hr to obtain enzyme-containing culture solution.
The inducer comprises ginsenoside Rb3, lentinus Edodes extract, cordyceps extract, and radix Glehniae extract according to the ratio of 1-3:1-2:2-3:1 to 1.4 mass ratio.
Step 3, extracting enzyme
After fermentation, the thalli are removed by centrifugation, and then the fermentation liquor is concentrated by an ultrafiltration membrane to remove impurities such as protein, salt, sugar and the like with molecular weight lower than 20kDa, thus obtaining crude enzyme.
Step 4, enzyme reaction
Dissolving crude enzyme in phosphate buffer solution with pH of 7.0 and 0.05M, wherein the mass ratio of the crude enzyme to the phosphate buffer solution is 1:48-52 to obtain the enzyme solution.
Rb3 with the mass percentage of 40% is added into a phosphate buffer solution with the concentration of 0.05M and the pH value of 7.0, and the mixture is fully dissolved to obtain a substrate. The mass ratio of Rb3 to phosphate buffer is 1:15-25. The Rb3: is commercially available.
Mixing the enzyme solution and the substrate solution according to the mass ratio of 1:1, and reacting for 18-26h at 35-38 ℃.
Step 5, purification
After fermentation, filtering to remove thalli, concentrating the culture solution to 5-20% of the volume of the culture solution to obtain concentrated solution. Adding 3-4 times of ethanol into the concentrated solution, oscillating for 20-30min, and centrifuging to retain centrifugate. The ethanol concentration was 95%.
Purifying the centrifugate with macroporous adsorption resin; after the saponin is adsorbed by the resin, washing to remove impurities; washing the column with 50% ethanol to remove polysaccharide-based saponin; then eluting the saponin with 95% alcohol, evaporating the eluent to dryness to obtain powder, namely the anti-aging composition.
An anti-wrinkle composition based on Sirt signaling pathways comprising the following components: ginsenoside CMc, ginsenoside CMx, and ginsenoside CK; the mass ratio is CMc: CMx: ck=1:10-15:3-4.
Compared with the traditional method, the invention has the following beneficial effects:
the anti-wrinkle composition based on the Sirt signal channel has an excellent anti-aging effect, can be used for preparing cosmetics such as emulsion, essence, nutrient solution, face cream and the like, can obviously promote the expression of Sirt1 protein, and has obvious anti-wrinkle and anti-wrinkle effects.
The nutrient solution prepared by the anti-wrinkle composition is used for skin care, and the number, the area and the length of wrinkles can be obviously reduced.
Drawings
FIG. 1 is an HPLC detection chart of the product of example 1;
FIG. 2 is an electrophoresis chart of the detection of liver Sirt1, FOXO1, PPARα, PGC1- α proteins in example 3;
FIG. 3 is a graph showing the analysis of Sirt1 content in the liver of the rat in example 3;
FIG. 4 is a graph showing the analysis of the amount of factor FOXO1 in the liver of the rat in example 3;
FIG. 5 is a graph showing the analysis of specific levels of peroxisome proliferator-activated receptor PPARα in the liver of rats in example 3;
FIG. 6 is a graph showing the analysis of specific content of hydrogen effector PGC 1-alpha in the liver of rats in example 3;
FIG. 7 is a photograph of Primos-CR canthus wrinkles in the test area of volunteers at days 0, 28, 56 of example 4;
FIG. 8 is a schematic of the mechanism by which Sirt signaling channels affect cell senescence.
Detailed Description
Example 1A method for preparing an anti-wrinkle composition based on Sirt signaling channels
The method comprises the following steps:
step 1, strain culture
Inoculating lactococcus lactis subspecies into a liquid culture medium under the conditions of normal temperature and normal pressure; the formula of the liquid culture medium is as follows:
yeast extract 7.5 g, glucose 10.0 g, tomato juice (pressed juice) 100.0 mL, protein wine 7.5 g, KH 2 PO 4 2.0g, tween 800.5 mL, distilled water 900.0 mL, pH 7.0.
The lactococcus lactis subspecies: the strain is commercially available and the strain preservation number is CICC 20402.
After inoculation, the cells were incubated at 37℃for 36 hours under aerobic conditions.
Step 2, fermenting to produce enzyme
After 36 hours of cultivation, the culture broth was transferred to a fermentation medium with an inoculum size of 1-2%.
The fermentation medium is as follows: 42.0g of ginseng total saponin, 5.0g of silkworm chrysalis meal, 4.0g of cow milk powder, 2.0g of soybean isoflavone, 2.0g of mannitol, 1.0g of citric acid diammonium, 1.0g of ascorbic acid, 12.0 g of vitamin B and K 2 HPO 4 0.3g、ZnSO 4 ·7H 2 O 0.2g、MnSO 4 ·H 2 O 0.05g、(NH 4 )SO 4 ·H 2 O 0.05g、Ca(NO 3 ) 2 1.0g of fucoidan, 6.0g of glutamic acid, 1.0L of distilled water and pH6.9. At 37 ℃ for 26 hours, then adding an inducer, shaking the culture medium uniformly after adding, and continuing to culture for 28 hours with the inducer added amount being 3% of the mass of the expanded culture medium to obtain the enzyme-containing culture solution.
The inducer comprises ginsenoside Rb3, lentinus Edodes extract, cordyceps extract, and radix Glehniae extract according to the following ratio of 2:1.5:3: 1.2, mixing.
Step 3, extracting enzyme
After fermentation, the thalli are removed by centrifugation, and then the fermentation liquor is concentrated by an ultrafiltration membrane to remove impurities such as protein, salt, sugar and the like with molecular weight lower than 20kDa, thus obtaining crude enzyme.
Step 4, enzyme reaction
Dissolving crude enzyme in phosphate buffer solution with pH of 7.0 and 0.05M, wherein the mass ratio of the crude enzyme to the phosphate buffer solution is 1:50, obtaining an enzyme solution.
Adding 40 mass percent of Rb3 into 0.05M phosphate buffer with pH of 7.0, and fully dissolving to obtain the substrate.
The mass ratio of Rb3 to phosphate buffer is 1:20. The Rb3: is commercially available.
The enzyme solution and the substrate are mixed according to the mass ratio of 1:1 and reacted for 20 hours at 37 ℃.
Step 5, purification
After fermentation, the bacterial cells are removed by filtration, and then the culture solution is concentrated to 10% of the volume of the culture solution, so as to obtain a concentrated solution. Adding 4 times of ethanol into the concentrated solution, oscillating for 20-30min, and centrifuging to retain centrifugate. The ethanol concentration was 95%.
Purifying the centrifugate with macroporous adsorption resin; after the saponin is adsorbed by the resin, washing to remove impurities; washing the column with 50% ethanol to remove polysaccharide-based saponin; then eluting the saponin with 95% alcohol, evaporating the eluent to dryness to obtain the product, namely the anti-aging composition. The product was subjected to HPLC detection, the HPLC detection pattern is shown in FIG. 1.
The detected product components comprise ginsenoside CMc, CMx, CK in mass ratio: CMc: CMx: ck=1:12:3.6.
Example 2 use of an anti-wrinkle composition based on Sirt signaling channels
Dissolving the anti-aging composition prepared in the example 1 in a solvent to prepare an anti-wrinkle nutrient solution; the mass ratio of the anti-aging composition to the solvent is 1:200.
The solvent is prepared from water, ethanol, glycerol and squalane according to the following ratio of 80:3:12:5 mass ratio.
Example 3 test of Effect of promoting protein expression on Sirt1 Signal pathway
The detection method comprises the following steps:
step 1, animal modeling grouping and administration
After the Wistar rats were adaptively fed for 1 week, they were randomly divided into 3 groups, 1 group was selected as a normal group, and the remaining 2 groups were subjected to modeling. The normal group was fed with normal feed for 6 weeks. The building block was fed with high fat diet for 6 weeks. 6. The rats were modeled after week on an empty stomach and were intraperitoneally injected with STZ 6mg/kg (dissolved in sodium citrate buffer, pH 4.5) to create a T2DM model. The normal group was intraperitoneally injected with the same amount of sodium citrate buffer as the modeling group. After injection 3 d, the random blood sugar is measured to be more than or equal to 16.7 mol/L, which indicates that the molding is successful. Rats with substandard blood sugar are continuously observed according to the previous steps after being subjected to intraperitoneal injection of 5 mg/kg STZ again, and if the blood sugar is not qualified after intraperitoneal injection for 2 times, the rats are killed under the anesthesia of the rejection molding module. After molding the model rats, they were randomly divided into model groups and drug administration groups.
Drug administration group: the composition prepared in example 1 was dissolved in distilled water to prepare a 0.1/mL solution, which was administered by gavage at a dose of 0.4. 0.4 g/kg. Rats in the normal and model groups were perfused with equal volumes of distilled water.
1. The stomach was irrigated continuously for 6 weeks at times/d.
Step 2, detecting liver Sirt1, FOXO1, PPARα, PGC1- α protein expression
Livers of rats in the normal group, model group, and administration group were collected. Cutting liver tissue, cleaning in 2 mL EP tube, adding 300L RIPA lysate, repeatedly grinding, and performing ice lysis for 10 min at 4deg.C. The supernatant was collected by centrifugation at 12000 r/min radius 8 cm for 15 min and protein concentration was determined by BCA protein quantification. Preparing 10% of separation gel and 4.8% of concentrated gel, adding TEMED, shaking and filling the gel, adding a total protein sample with a corresponding volume, mixing with 5x protein gel electrophoresis loading buffer solution, boiling for denaturation, transferring to PVDF membrane, sealing in sealing solution for 90 min, adding Sirt1, FOXO1, PPARα and PGC1- α antibodies, standing overnight at 4 ℃, washing with TBST for 3 times, 10 min each time, adding secondary antibody for incubation for 90 min, washing the membrane, incubating ECL chemiluminescent solution with the membrane for 1min, imaging by a gel imaging system, and detecting the result is shown in figure 2.
The analysis chart of Sirt1 content in livers of rats in the normal group, the model group and the administration group is shown in figure 3; the analysis chart of the content of the transcription factor FOXO1 in the livers of the normal group, the model group and the administration group rats is shown in figure 4; the specific content analysis chart of peroxisome proliferator-activated receptor PPARα in the livers of the normal group, model group and administration group rats is shown in FIG. 5; the analysis of the specific content of the hydrogen effector molecule PGC 1-alpha in the livers of the rats in the normal group, the model group and the administration group is shown in FIG. 6.
Analysis of FIG. 2 shows that the levels of Sirt1, FOXO1, PPARα, and PGC1- α were significantly lower in the model group than in the normal group, indicating that expression of Sirt1, FOXO1, PPARα, and PGC1- α was affected in the rats after modeling. The levels of Sirt1, FOXO1, pparα, PGC1- α were significantly higher in the administered group than in the model group, demonstrating that intervention of the saponin composition prepared in example 1 effectively increased the expression of Sirt1, FOXO1, pparα, PGC1- α in rats, i.e., the saponin composition prepared in example 1 significantly upregulated the expression of proteins on the Sirt1 signaling pathway.
As can be seen from FIG. 2, the amount of protein expressed on the Sirt1 signal pathway in the rats of the administration group was 2 times or more that in the model group.
Example 4 anti-wrinkle nutrient solution use Effect experiment
30 volunteers were recruited for the anti-wrinkle nutrient solution trial experiment prepared in example 2, numbered VT001-VT056, respectively; from the first day of the experiment, volunteers used anti-wrinkle nutrient solution for skin care three times a day in the morning, in the middle and at night, without using other skin care products at the same time during the experiment. The number of Primos-CR canthus wrinkles, the area of wrinkles, and the length of wrinkles in the tested area of volunteers were measured and counted daily for 56 days. Photographs of Primos-CR canthus wrinkles of the tested area of VT001, VT006, VT026 volunteers at days 0, 28, 56 were taken at random, as shown in FIG. 7.
1. The average value of the number of wrinkles at the corners of the eyes of the volunteer was measured and calculated before the experiment and was taken as a base value D0. On day 28 of the product, the average D28 of the number of wrinkles at the corners of the volunteer's eyes was detected and calculated. On day 56 of the product, the average D56 of the number of wrinkles at the corners of the volunteer's eyes was detected and calculated. The results (mean.+ -. Standard error) of the number of Primos-CR canthus wrinkles in the volunteer test areas at day 0, 28, 56 of the experiment are shown in Table 1;
TABLE 1
Note that: data in the table are mean ± standard error
Calculating the change rate of the number of wrinkles at the canthus for 28 days using the product and the change rate of the number of wrinkles at the canthus for 56 days using the product, as shown in table 2;
rate of change in number of canthus wrinkles on day n= (average number of canthus wrinkles after day N using product-average number of canthus wrinkles on day 0) ×100%/average number of canthus wrinkles on day 0
TABLE 2
The significance of the results of the number of wrinkles at the corners of the eyes of the volunteers in this experiment is shown in Table 3;
TABLE 3 Table 3
Note that: statistical method analysis was performed using a rank sum test and t test method, with test level a=0.05.
The significance labeling method is that "n.s" indicates no statistical difference, p >0.05, p <0.05 indicates significant difference (". Times." indicates that 0.01.ltoreq.p <0.05; ". Times." indicates that 0.001.ltoreq.p <0.01; ". Times." indicates that p < 0.001), and the number of products is used=30.
As shown in tables 1 to 3, after the volunteers continuously use the product anti-wrinkle nutrient solution for 28 days and 56 days, the number of Primos-CR canthus wrinkles in the tested area is remarkably reduced (p < 0.001) compared with the basic value, and the reduction rates are 27.52% and 44.97% respectively. The anti-wrinkle nutrient solution provided by the invention can effectively reduce the number of wrinkles, and has a remarkable anti-aging effect.
2. The average value of the volunteer's canthus wrinkle volume was measured and calculated prior to the experiment and taken as the base value D0. After 28 days of use of the product, the average D28 of the volunteer's corner of eye wrinkle volume was detected and calculated. After 56 days of use of the product, the average D56 of the volunteer's corner of eye wrinkle volume was detected and calculated. The results of the test (mean.+ -. Standard error) of the volume of Primos-CR canthus wrinkles in the volunteer test area at day 0, 28, 56 of the experiment are shown in Table 4;
TABLE 4 Table 4
Note that: data in the table are mean ± standard error
Calculating the change rate of the volume of the canthus wrinkles in 28 days of using the product and the change rate of the volume of the canthus wrinkles in 56 days of using the product, as shown in table 5;
rate of change in volume of corner of eye wrinkles on day n= (average of corner of eye wrinkles after day N using product-average of corner of eye wrinkles on day 0) ×100%/average of corner of eye wrinkles on day 0
TABLE 5
The significance of the results of the volume detection of the wrinkles at the corners of the eyes of the volunteers in this experiment is shown in Table 6;
TABLE 6
Note that: statistical method analysis was performed using a rank sum test and t test method, with test level a=0.05.
The significance labeling method is that "n.s" indicates no statistical difference, p >0.05, p <0.05 indicates significant difference (". Times." indicates that 0.01.ltoreq.p <0.05; ". Times." indicates that 0.001.ltoreq.p <0.01; ". Times." indicates that p < 0.001), and the number of products is used=30.
As can be seen from tables 4 to 6, volunteers continuously used the product anti-wrinkle nutrient solution for 28 days, the Primos-CR canthus wrinkle volume in the tested area was significantly reduced (0.01 Sp < 0.05) from the basal value, the reduction rate was 11.67%, and the Primos-CR canthus wrinkle volume in the tested area was significantly reduced (p < 0.001) from the basal value, the reduction rate was 17.56% after the volunteers continuously used the product anti-wrinkle nutrient solution for 56 days.
3. The average value of the length of the wrinkles at the corners of the eyes of the volunteers was measured and calculated before the experiment and was taken as a base value D0. After 28 days of use of the product, the average value D28 of the length of the wrinkles at the corners of the eyes of the volunteers was detected and calculated. After 56 days of use of the product, the average value D56 of the length of the wrinkles at the corners of the eyes of the volunteers was detected and calculated. The results of the test (mean.+ -. Standard error) of the length of Primos-CR canthus wrinkles in the volunteer test areas at day 0, 28, 56 of the experiment are shown in Table 7;
TABLE 7
Note that: data in the table are mean soil standard error
Calculating the change rate of the length of the canthus wrinkle in 28 days of using the product and the change rate of the length of the canthus wrinkle in 56 days of using the product, as shown in table 8;
rate of change in length of corner wrinkles at day n= (average value of corner wrinkles after day N using product-average value of corner wrinkles at day 0) ×100%/average value of corner wrinkles at day 0
TABLE 8
The significance of the results of the test volunteer's canthus wrinkle length is shown in table 9;
TABLE 9
Note that: statistical method analysis was performed using a rank sum test and t test method, with test level a=0.05.
The significance labeling method is that "n.s" indicates no statistical difference, p >0.05, p <0.05 indicates significant difference (". Times." indicates that 0.01.ltoreq.p <0.05; ". Times." indicates that 0.001.ltoreq.p <0.01; ". Times." indicates that p < 0.001), and the number of products is used=30.
As shown in tables 7-9, the Primos-CR eye corner wrinkle length of the tested area in 28 days and 56 days of continuous use of the product anti-wrinkle nutrient solution by the volunteers is remarkably reduced (p is more than or equal to 0.001 and less than or equal to 0.01) compared with the base value, and the reduction rates are respectively 10.21 percent and 11.34 percent.
The control conditions for HPLC detection described in the present invention are as follows: the detection wavelength is 203nm. Mobile phase acetonitrile (a) -water (B): 0-20min,20% A,20-31min, 20-32% A,31-40min, 32-43% A,40-47min, 43-100% A. Column temperature was 35 ℃.
The raw materials adopted by the invention are all from commercial sources. The ginseng total saponins: the saponin content is 80%, the product model is HS-376, the gramineous organism; the Lentinus edodes extract comprises the following components: polysaccharide content 50%, model WYT; the Cordyceps extract comprises: polysaccharide content 30%, product model RC2303008; the radix glehniae extract: specification 30:1, product model BSSTQW01.
Except for specific descriptions, the proportions of the invention are mass ratios, and the percentages are mass percentages.
It is apparent that there are many more specific embodiments that can be varied within the inventive concept, and it should be stated herein that any modification made within the inventive concept of the present invention will fall within the scope of the present invention.
Claims (10)
1. A method of preparing an anti-wrinkle composition based on Sirt signaling pathways, comprising: comprises the steps of strain culture, enzyme production by fermentation, enzyme extraction, enzyme reaction and purification; the strain is lactococcus lactis subspecies lactis.
2. A method of preparing an anti-wrinkle composition based on Sirt signal pathways according to claim 1, wherein: the fermentation produces enzyme: the fermentation temperature is 36-38 ℃, and after culturing for 24-28 hours, the inducer is added for continuous culturing for 24-36 hours, thus obtaining the enzyme-containing culture solution.
3. A method of preparing an anti-wrinkle composition based on Sirt signal pathways according to claim 2, characterized in that: the inducer comprises ginsenoside Rb3, lentinus Edodes extract, cordyceps extract, and radix Glehniae extract.
4. A method of preparing an anti-wrinkle composition based on Sirt signal pathways according to claim 3, wherein: the proportion of the ginsenoside Rb3, the mushroom extract, the cordyceps extract and the glehnia root extract is 1-3:1-2:2-3:1-1.4.
5. A method of preparing an anti-wrinkle composition based on Sirt signal pathways according to claim 1, wherein: the enzyme reaction: mixing the enzyme solution with the substrate, and reacting at 35-38 ℃ for 18-26h.
6. A method of preparing an anti-wrinkle composition based on Sirt signal pathways according to claim 1, wherein: the enzyme reaction: dissolving crude enzyme in phosphate buffer solution, wherein the mass ratio of the crude enzyme to the phosphate buffer solution is 1:48-52 to obtain the enzyme solution.
7. A method of preparing an anti-wrinkle composition based on Sirt signal pathways according to claim 1, wherein: the enzyme reaction: adding Rb3 into phosphate buffer solution, and fully dissolving to obtain a substrate; the mass ratio of Rb3 to phosphate buffer is 1:15-25.
8. A method of preparing an anti-wrinkle composition based on Sirt signal pathways according to claim 1, wherein: the fermentation produces enzyme: the fermentation medium adopted comprises the following components: total ginsenoside, pupa Bombycis powder, milk powder, soybean isoflavone, mannitol, diammonium citrate, ascorbic acid, vitamin B12, K 2 HPO 4 、ZnSO 4 ·7H 2 O、MnSO 4 ·H 2 O、(NH 4 )SO 4 ·H 2 O、Ca(NO 3 ) 2 Fucoidan, glutamic acid.
9. An anti-wrinkle composition based on Sirt signaling pathways, characterized by: the composition comprises the following components: ginsenoside CMc, ginsenoside CMx, and ginsenoside CK.
10. An anti-wrinkle composition based on Sirt signaling pathway according to claim 9, wherein: the mass ratio of the ginsenoside CMC to the ginsenoside CMx to the ginsenoside CK is 1:10-15:3-4.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311439515.7A CN117442510A (en) | 2023-11-01 | 2023-11-01 | Anti-wrinkle composition based on Sirt signal channel, and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311439515.7A CN117442510A (en) | 2023-11-01 | 2023-11-01 | Anti-wrinkle composition based on Sirt signal channel, and preparation method and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117442510A true CN117442510A (en) | 2024-01-26 |
Family
ID=89588804
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311439515.7A Pending CN117442510A (en) | 2023-11-01 | 2023-11-01 | Anti-wrinkle composition based on Sirt signal channel, and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117442510A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117899098A (en) * | 2024-03-19 | 2024-04-19 | 昆明之诺医药科技有限公司 | Application of rare ginsenoside CMx in preparation of medicine for preventing and/or treating type 2 inflammatory diseases |
-
2023
- 2023-11-01 CN CN202311439515.7A patent/CN117442510A/en active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117899098A (en) * | 2024-03-19 | 2024-04-19 | 昆明之诺医药科技有限公司 | Application of rare ginsenoside CMx in preparation of medicine for preventing and/or treating type 2 inflammatory diseases |
CN117899098B (en) * | 2024-03-19 | 2024-05-17 | 昆明之诺医药科技有限公司 | Application of rare ginsenoside CMx in preparation of medicine for preventing and/or treating type 2 inflammatory diseases |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104013657B (en) | A kind of American ginseng medicine extracts after saponin(e microbial fermentation extracting method again | |
CN117442510A (en) | Anti-wrinkle composition based on Sirt signal channel, and preparation method and application thereof | |
CN108403498A (en) | A kind of preparation method and applications of natto extracting solution | |
CN107541533A (en) | A kind of preparation method of medicine food hypha polysaccharide polypeptide immunopotentiator | |
CN1261585C (en) | Method for preparing isoquercetin and quercetin by enzymatic method and hydrolyzing rutin | |
CN100394928C (en) | Application of Antrodia camphorata mycelium fermented extract in preparation of anti-radiation damage medicine | |
CN104522750A (en) | Alga healthcare food | |
CN115317432B (en) | Mask containing bifidobacterium lactis fermentation product | |
CN109439719A (en) | A kind of fungi two-way solid-fermented technique and its application based on Cortex Eucommiae | |
TWM590969U (en) | Particle structure of rutaceae plant fermentation broth with biomimetic stroma system | |
CN111150754B (en) | Application of chestnut flower extract in preparation of food or anti-inflammatory drugs | |
CN113398163B (en) | Fermentation method of Chinese herbal medicine and application of fermentation product | |
CN101347465B (en) | Xylaria nigripes fermentation liquor powder and preparation and use | |
CN1940064A (en) | Production of thrombolytic kinase (natto kinase) and its use | |
CN112675288A (en) | Traditional Chinese medicine enzyme and preparation method thereof | |
CN115282185B (en) | Fermented salvia miltiorrhiza extract containing salvia miltiorrhiza enzymes, and preparation method and application thereof | |
CN115005442B (en) | Preparation method and application of saussurea involucrata polysaccharide extract | |
CN113398026B (en) | Golden fungus ginseng fermentation leaching liquor with oxidation resistance | |
CN117298177B (en) | Natural immunomodulator and preparation method thereof | |
CN117562258B (en) | Application of animal bifidobacterium subspecies in promoting ginseng extract to play role in relieving liver injury | |
CN1350860A (en) | Process for preparing health-care oral liquid for diabetics | |
CN109400679B (en) | Blood fat reducing hexapeptide derived from spotted maigre swimming bladder and application thereof | |
KR960012396B1 (en) | Animal feed additive and method for producing the same | |
CN116999471A (en) | Blood sugar reducing composition and preparation method and application thereof | |
CN116640814A (en) | Inonotus obliquus crude and pure polysaccharide and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |